Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer

RR (Roy) Jurhill; H de Veen; Arno van Leenders; Paul Verhagen

doi:10.1016/j.eururo.2009.02.025

Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer

RR (Roy) Jurhill, H de Veen, Arno van Leenders, Paul Verhagen

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

We present two prostate cancer patients, including one with a castration-resistant cancer whose rising serum prostate-specific antigen (PSA) levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir. In one patient, we found a temporary decrease in serum PSA lasting for at least 4 mo. In the patient with castration-resistant prostate cancer, serum PSA decreased to <0.01 mu g/l and has remained undetectable since. (C) European Association of Urology Published by Elsevier B.V. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	392-394
Number of pages	3
Journal	European Urology
Volume	56
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2009.02.025
Publication status	Published - 2009

Research programs

EMC MM-03-24-01
EMC MM-03-49-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2009.02.025

http://hdl.handle.net/1765/27006

Cite this

@article{cff218a5b1eb455ea6db9027506efd90,

title = "Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer",

abstract = "We present two prostate cancer patients, including one with a castration-resistant cancer whose rising serum prostate-specific antigen (PSA) levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir. In one patient, we found a temporary decrease in serum PSA lasting for at least 4 mo. In the patient with castration-resistant prostate cancer, serum PSA decreased to <0.01 mu g/l and has remained undetectable since. (C) European Association of Urology Published by Elsevier B.V. All rights reserved.",

author = "Jurhill, \{RR (Roy)\} and \{de Veen\}, H and \{van Leenders\}, Arno and Paul Verhagen",

year = "2009",

doi = "10.1016/j.eururo.2009.02.025",

language = "Undefined/Unknown",

volume = "56",

pages = "392--394",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer

AU - Jurhill, RR (Roy)

AU - de Veen, H

AU - van Leenders, Arno

AU - Verhagen, Paul

PY - 2009

Y1 - 2009

N2 - We present two prostate cancer patients, including one with a castration-resistant cancer whose rising serum prostate-specific antigen (PSA) levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir. In one patient, we found a temporary decrease in serum PSA lasting for at least 4 mo. In the patient with castration-resistant prostate cancer, serum PSA decreased to <0.01 mu g/l and has remained undetectable since. (C) European Association of Urology Published by Elsevier B.V. All rights reserved.

AB - We present two prostate cancer patients, including one with a castration-resistant cancer whose rising serum prostate-specific antigen (PSA) levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir. In one patient, we found a temporary decrease in serum PSA lasting for at least 4 mo. In the patient with castration-resistant prostate cancer, serum PSA decreased to <0.01 mu g/l and has remained undetectable since. (C) European Association of Urology Published by Elsevier B.V. All rights reserved.

U2 - 10.1016/j.eururo.2009.02.025

DO - 10.1016/j.eururo.2009.02.025

M3 - Article

C2 - 19278776

SN - 0302-2838

VL - 56

SP - 392

EP - 394

JO - European Urology

JF - European Urology

IS - 2

ER -